nach oben

Erschienen in:

21.07.2020 | Original Article

The effect of botulinum toxin on ureteral inflammation

verfasst von: Kevin Krughoff, Faith L. Anderson, Scott Palisoul, Alison L. Young, Jason R. Pettus, Karen L. Moodie, Christopher Ogomo, Steven S. Tau, Rachel A. Moses, Matthew C. Havrda, David R. Chavez

Erschienen in: World Journal of Urology | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The impact of onabotulinum toxin type A (BoNT-A) on bladder afferent nerve pathways and chemosensory functions is an active area of investigation. There may be a role for BoNT-A in disorders of the ureter; however, no histologic studies have assessed the effects of BoNT-A on ureteral tissue. Our objective was to develop an animal model of ureteral inflammation and determine the impact of ureteral BoNT-A instillation on known mechanisms of inflammation.

Methods

The safety and feasibility of a novel animal model of ureteral inflammation was assessed. Through open cystotomy, the effect of ureteral BoNT-A instillation on inflammation was determined through H&E, masson’s trichrome, Ki-67 stain, and prostaglandin E (PGE) synthase expression, a known marker of pain and inflammation in ureteral tissue. Urothelial microstructure was assessed using electron microscopy and standard histologic techniques.

Results

All experiments were carried to completion, and no systemic signs of botulinum toxicity were seen. BoNT-A exposure was associated with a decrease in PGE synthase expression in a dose-dependent fashion. BoNT-A exposure was not found to impact collagen deposition or cell proliferation. Disruption of tight junctions between urothelial cells was observed under conditions of inflammation.

Conclusion

We describe the feasibility of a novel in vivo model of ureteral inflammation and report the first histologic study of the effects of BoNT-A on the ureter. Preliminary findings show that BoNT-A attenuates ureteral PGE synthase expression under conditions of inflammation. The application of BoNT-A may provide anti-inflammatory and analgesic effects in the context of ureteral disorders.

Nitti VW, Dmochowski R, Herschorn S et al (2013) OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urology 189:2186–2193. https://doi.org/10.1016/j.juro.2012.12.022CrossRef

Chuang Y-C, Kaufmann JH, Chancellor DD et al (2014) Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial. J Urology 192:1743–1749. https://doi.org/10.1016/j.juro.2014.07.008CrossRef

Chermansky CJ, Chancellor MB (2016) Use of botulinum toxin in urologic diseases. Urology 91:21–32. https://doi.org/10.1016/j.urology.2015.12.049CrossRefPubMed

Bossowska A, Lepiarczyk E, Mazur U et al (2015) Botulinum toxin type A induces changes in the chemical coding of substance P-immunoreactive dorsal root ganglia sensory neurons supplying the porcine urinary bladder. Toxins 7:4797–4816. https://doi.org/10.3390/toxins7114797CrossRefPubMedPubMedCentral

Lavin ST, Southwell BR, Murphy R et al (1998) Activation of neurokinin 1 receptors on interstitial cells of Cajal of the guinea-pig small intestine by substance P. Histochem Cell Biol 110:263–271. https://doi.org/10.1007/s004180050288CrossRefPubMed

Atiemo H, Wynes J, Chuo J et al (2005) Effect of botulinum toxin on detrusor overactivity induced by intravesical adenosine triphosphate and capsaicin in a rat model. Urology 65:622–626. https://doi.org/10.1016/j.urology.2004.10.057CrossRefPubMed

Kajbafzadeh A-M, Montaser-Kouhsari L, Ahmadi H, Sotoudeh M (2011) Intravesical electromotive botulinum toxin type a administration: part I—experimental study. Urology 77:1460–1464. https://doi.org/10.1016/j.urology.2010.09.036CrossRefPubMed

Collins VM, Daly DM, Liaskos M et al (2013) OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium. Bju Int 112:1018–1026. https://doi.org/10.1111/bju.12266CrossRefPubMed

Jhang J-F, Kuo H-C (2016) Botulinum toxin a and lower urinary tract dysfunction: pathophysiology and mechanisms of action. Toxins 8:120. https://doi.org/10.3390/toxins8040120CrossRefPubMedPubMedCentral

10.

Gosling JA, Dixon JS (1974) Sensory nerves in the mammalian urinary tract. An evaluation using light and electron microscopy. J Anat 117:133–144PubMedPubMedCentral

11.

Hoyes AD, Bourne R, Martin BG (1975) Ultrastructure of the submucous nerves of the rat ureter. J Anat 119:123–132PubMedPubMedCentral

12.

Vernez SL, Okhunov Z, Wikenheiser J et al (2017) Precise characterization and 3-dimensional reconstruction of the autonomic nerve distribution of the human ureter. J Urology 197:723–729. https://doi.org/10.1016/j.juro.2016.08.118CrossRef

13.

Liang F-X, Bosland MC, Huang H et al (2005) Cellular basis of urothelial squamous metaplasia. J Cell Biol 171:835–844. https://doi.org/10.1083/jcb.200505035CrossRefPubMedPubMedCentral

14.

Trebino CE, Stock JL, Gibbons CP et al (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc National Acad Sci 100:9044–9049. https://doi.org/10.1073/pnas.1332766100CrossRef

15.

Huntjens DRH, Danhof M, Pasqua OED (2005) Pharmacokinetic–pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors. Rheumatology 44:846–859. https://doi.org/10.1093/rheumatology/keh627CrossRefPubMed

16.

Rastogi P, Rickard A, Dorokhov N et al (2008) Loss of prostaglandin E 2 release from immortalized urothelial cells obtained from interstitial cystitis patient bladders. Am J Physiol-renal 294:F1129–F1135. https://doi.org/10.1152/ajprenal.00572.2007CrossRef

17.

Montaser-Kouhsari L, Kajbafzadeh AM, Ahmadi H, Sotoudeh M (2010) Intravesical electromotive botulinum toxin-a administration: an experimental study. J PediatrUrol 6:S19–S20. https://doi.org/10.1016/j.jpurol.2010.02.010CrossRef

18.

Krhut J, Zvara P (2011) Intravesical instillation of botulinum toxin A: an in vivo murine study and pilot clinical trial. Int UrolNephrol 43:337–343. https://doi.org/10.1007/s11255-010-9790-zCrossRef

19.

Merrill L, Gonzalez EJ, Girard BM, Vizzard MA (2016) Receptors, channels, and signalling in the urothelial sensory system in the bladder. Nat Rev Urol 13:193–204. https://doi.org/10.1038/nrurol.2016.13CrossRefPubMedPubMedCentral

20.

Gupta M, Patel T, Xavier K et al (2010) Prospective randomized evaluation of periureteral botulinum toxin type a injection for ureteral stent pain reduction. J Urology 183:598–602. https://doi.org/10.1016/j.juro.2009.10.021CrossRef

21.

Streeper NM, Nakada SY, Wertheim ML, Best SL (2016) Preliminary evidence suggests periureteral botulinum toxin type a injection improves ureteral stone passage in the porcine model. J Endourol 30:327–331. https://doi.org/10.1089/end.2015.0249CrossRefPubMed

22.

Murakami M, Nakatani Y, Tanioka T, Kudo I (2002) Prostaglandin E synthase. ProstagOth Lipid M 68:383–399. https://doi.org/10.1016/s0090-6980(02)00043-6CrossRef

23.

Huang Z-A, Scotland KB, Li Y et al (2020) Determination of urinary prostaglandin E2 as a potential biomarker of ureteral stent associated inflammation. J Chromatogr B 1145:122107. https://doi.org/10.1016/j.jchromb.2020.122107CrossRef

24.

Hokanson JA, Langdale CL, Sridhar A, Grill WM (2017) OAB without an Overactive Bladder in the acute prostaglandin E2 rat model. Am J Physiology Ren Physiology 313:270. https://doi.org/10.1152/ajprenal.00270.2017CrossRef

25.

Hegele A, Knippschild S, Frohme C et al (2014) Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit? BmcUrol 14:85. https://doi.org/10.1186/1471-2490-14-85CrossRef

26.

Kamei D, Yamakawa K, Takegoshi Y et al (2004) Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin E synthase-1. J Biol Chem 279:33684–33695. https://doi.org/10.1074/jbc.m400199200CrossRefPubMed

27.

HARA S (2017) Prostaglandin terminal synthases as novel therapeutic targets. Proc JpnAcad Ser B 93:703–723. https://doi.org/10.2183/pjab.93.044CrossRef

28.

Lowry PS, Jerde TJ, Bjorling DE et al (2005) Obstruction alters the effect of prostaglandin E2 on ureteral contractility. J Endourol 19:183–187. https://doi.org/10.1089/end.2005.19.183CrossRefPubMed

29.

Erickson DR, Herb N, Ordille S et al (2000) A new direct test of bladder permeability. J Urology 164:419–422. https://doi.org/10.1016/s0022-5347(05)67375-2CrossRef

30.

Rhéaume C, Cai BB, Wang J et al (2015) A highly specific monoclonal antibody for botulinum neurotoxin type a-cleaved SNAP25. Toxins 7:2354–2370. https://doi.org/10.3390/toxins7072354CrossRefPubMedPubMedCentral

Titel: The effect of botulinum toxin on ureteral inflammation
verfasst von: Kevin Krughoff
Faith L. Anderson
Scott Palisoul
Alison L. Young
Jason R. Pettus
Karen L. Moodie
Christopher Ogomo
Steven S. Tau
Rachel A. Moses
Matthew C. Havrda
David R. Chavez
Publikationsdatum: 21.07.2020
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 6/2021
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-020-03365-y

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2021

Clinical outcome of robot-assisted residual mass resection in metastatic nonseminomatous germ cell tumor

Perioperative outcomes and safety of robotic vs open cystectomy: a systematic review and meta-analysis of 12,640 cases

Circulating preoperative testosterone level predicts unfavourable disease at radical prostatectomy in men with International Society of Urological Pathology Grade Group 1 prostate cancer diagnosed with systematic biopsies

Intrasphincteric anastomotic urethroplasty allows preservation of continence in men with bulbomembranous urethral strictures following benign prostatic hyperplasia surgery